PharmaCyte Biotech Inc (PMCB)

[Triple9]

The longer PMCB takes to reach market the more time it gives competitors to come up with a rival treatment.

Correct. At least 3 PRIVATE companies have been granted Orphan drug designation on pancreatic cancer since PMCB was issued it's designation. Tick Toc as everyone likes to write.

It seems to me there are numerous people on this board who would be absolutely ecstatic to see a competitor file an IND before PMCB.

Therefore:

1. PMCB has to balance releasing information for shareholders with releasing information to competitors.

2. PMCB investors should think long and hard when being encouraged by individuals who openly want to see PMCB crash and burn.

3. It is perfectly reasonable to assume the various private competitors of PMCB to, at best, monitor this board and, at worst, participate in this board for the benefit of their companies. Being private companies, with zero SEC oversight, means they can employ ANY means of beating PMCB.